Ebrotidine

CAS No. 100981-43-9

Ebrotidine ( FI3542 )

Catalog No. M26675 CAS No. 100981-43-9

Ebrotidine is a competitive H2-receptor antagonist with Ki of 127.5 nM. Ebrotidine has a potent antisecretory activity and evidenced gastroprotection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 33 Get Quote
5MG 53 Get Quote
10MG 87 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ebrotidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Ebrotidine is a competitive H2-receptor antagonist with Ki of 127.5 nM. Ebrotidine has a potent antisecretory activity and evidenced gastroprotection.
  • Description
    Ebrotidine is a competitive H2-receptor antagonist with Ki of 127.5 nM. Ebrotidine has a potent antisecretory activity and evidenced gastroprotection.(In Vitro):Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors, showing a higher affinity than ranitidine (Ki = 190.0 nM) and cimetidine (Ki = 246.1 nM) .(In Vivo):Ebrotidine inhibited histamine- (ED50: 0.21 mg/kg) and pentagastrin- (ED50: 0.44 mg/kg) stimulated acid secretion in a dose-dependent manner in rats . Ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Ebrotidine evoked 30% increase in mucus gel dimension, and showed 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%) . The mean number of gastric erosions seen at endoscopy after treatment with Ebrotidine plus ASA (2.0 +/- 0.3) was obviously lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by Ebrotidine was accompanied by a significant increase in gastric blood flow (by 15% in corpus and 26% in antrum), by a rise in transmucosal potential difference (by 12%), and by a decrease of mucosal microbleeding.
  • Synonyms
    FI3542
  • Pathway
    GPCR/G Protein
  • Target
    Histamine Receptor
  • Recptor
    Human Endogenous Metabolite; Nucleoside Antimetabolite/Analog
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    100981-43-9
  • Formula Weight
    477.4
  • Molecular Formula
    C14H17BrN6O2S3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.1-Methylinosine-Human Metabolome Database.
molnova catalog
related products
  • Pitolisant oxalate

    A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM; no effect on H1, H2, H4 receptors (IC50>10 uM).

  • JNJ-5207852 dihydroc...

    JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi=8.9) and human (pKi=9.24) H3 receptor. JNJ-5207852 is a potent dibasic amine antagonist that binds potently to rat H3 receptors (Ki=1.2?nm), and has good brain penetration. In ex vivo binding studies in mice, the compound had an ED50 of 0.13?mg?kg?1, subcutaneously.

  • Sodium butanoate

    Sodium Butyrate(Butanoic acid sodium salt) has been reported to cause hyperacetylation of histones due to its role as a histone deacetylase (HDAC) inhibitor (IC50 values are 0.3, 0.4, 0.3, mM for HDAC1, 2 and 7 respectively).